The disclosure discloses Bacteroides fragilis for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides fragilis CCFM1020 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of hosts infected with endotoxin, up-regulate the number of Foxp3.sup.+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides fragilis CCFM1020 for relieving endotoxin infection has broad application prospects.

A particular Bifidobacterium spp. strain or particular Lactobacillus spp. strain according to the present invention is isolated from excrement of a human or cabbage kimchi, and thus is highly safe and has physiological activities such as an immunity regulatory effect and an inflammation reaction inhibiting effect. Therefore, the particular Bifidobacterium spp. strain or particular Lactobacillus spp. strain according to the present invention may be used as a material for regulating immunity and inhibiting inflammation reactions, and may be also used as a functional food and drug material useful for preventing, alleviating or treating rhinitis, atopy, asthma, etc. which are allergic diseases.

This disclosure provides microbes engineered to detect virulent and spore states of pathogens and release an appropriate therapeutic response accordingly and compositions and methods of use of the same.

Provided herein are compositions and methods for the inhibition of enteric infection. In particular, compositions comprising bacteria of the class Clostridia are administered to human and/or animal subjects to prevent or decrease susceptibility to enteric infection.

The present invention relates to mixtures, or compositions comprising said mixtures, comprising at least one bacterial strain, preferably at least one probiotic bacterial strain or a derivative thereof, as well as to the use of said mixtures or compositions in methods for the preventive and/or curative treatment of an inflammatory ocular and/or periocular lesion, preferably in methods for the treatment of ocular diseases such as dry eyes, eyelid allergy, conjunctivitis, blepharitis, meibonite, dacryoliths, stye, inflammatory lesions of ocular adnexa and associated symptoms.

Probiotic compositions capable of generating a high CFU count and methods to improve the health of a subject including to treat or prevent a viral infection are disclosed.

The present invention provides for compositions and methods for treating colorectal cancer or for reducing the risk of developing the disease in an individual.

The present invention relates to the use of bacterial compositions having an arginine deaminase activity (inhibition of nitric oxide synthase by conversion of L-arginine to L-citrulline) of 1-1,000 μmol L-citrulline/h/g composition and a sphingomyelinase (ceramide generation) activity of 0.01-1.000 nmoles ceramides/h/g composition in the treatment and/or prophylaxis of airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (VRS), rhinoviruses, pneumoviruses, or respiratory failure induced or aggravated by viral infections, angina pectoris, pulmonary heart, respiratory distress, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure Pickwick syndrome, pulmonary hypertension, pneumonia or even cystic fibrosis (CF) aggravated by viral infections.

The disclosure provides novel microorganisms, such as Lactobacillus sp., Bifidobacterium sp., and Veillonella sp., and compositions thereof for improving athletic performance, enhancing exercise endurance, improving physical recovery from exercise, and reducing inflammation in a subject in need thereof.

Compositions comprising lactoferrin are described herein, which can allow for the use of ingredients in a formulation that previously could not be used, or combined together without encountering stability problems. The lactoferrin can also be included so as to eliminate the need for capsule-in-capsule formulations or embodiments comprising lactoferrin and a probiotic. As described herein, certain embodiments of the disclosure can comprise an active ingredient. An active ingredient can comprise one or more of a probiotic formulation, nutritional supplement, and a foodstuff. In certain embodiments, a probiotic formulation, nutritional supplement, and/or foodstuff. In certain embodiments, an active ingredient is a high water activity ingredient.